On Thursday, Jacobs Engineering Group Inc(NYSE:JEC)’s shares inclined 0.93% to $40.34.
Jacobs Engineering Group Inc. (JEC) declared recently it was selected by ExxonMobil to perform engineering, procurement and construction administration (EPCM) services for its Crude Flexibility Engineering and Construction Project at the ExxonMobil Refinery in Beaumont, Texas.
Company officials did not disclose the contract value, but noted that this project is a release against an existing long-term agreement.
The project aims to expand crude oil throughput at ExxonMobil’s Beaumont refinery, enhance production in the jet fuel unit, and optimize energy usage by enabling the crude unit to run different crude slates.
Jacobs Engineering Group Inc. provides technical, professional, and construction services to various industrial, commercial, and governmental clients. It offers project services that comprise engineering, design, architectural, interiors, planning, environmental, and other services; and process, scientific, and systems consulting services, counting services performed in connection with scientific testing, analysis, and consulting activities, in addition to information technology, and systems engineering and integration activities.
Intercontinental Exchange Inc(NYSE:ICE)’s shares gained 1.08% to $228.90.
The New York Stock Exchange, part of the Intercontinental Exchange (ICE) global network of exchanges, remained the leading exchange globally for capital raising in the first half of 2015, with 264 transactions raising a total of $94 billion, more than any other exchange in the world. This comprises 42 companies that raised $12 billion from initial public offerings (IPOs) in the first half of 2015.
With leadership across multiple sectors, NYSE led with 100% of REIT IPOs and 70% of all private equity (PE)-backed IPO proceeds, while gaining momentum in healthcare, counting one of the largest biotech IPOs ever. Comprising with its leadership in technology IPOs since 2012, the NYSE welcomed 10 technology IPOs raising $2.6 billion, which represents 66% of all capital raised from U.S. tech IPOs. Additionally, more than 85% of exchange traded products (ETPs) listed on NYSE Arca during the first half of the year.
Intercontinental Exchange, Inc. operates a network of regulated exchanges and clearing houses for financial and commodity markets in the United States, the United Kingdom, Continental Europe, Israel, Canada, and Singapore. The company operates marketplaces for trading and clearing a range of securities and derivatives contracts in various asset classes, counting energy and agricultural commodities, interest rates, equities, equity derivatives, credit derivatives, bonds, and currencies. It primarily provides trade execution, listing, price discovery and transparency, trade processing and repositories, clearing, benchmark administration, and market data services .
At the end of Thursday’s trade, Freshpet Inc(NASDAQ:FRPT)‘s shares surged 1.37% to $12.58.
Freshpet, Inc. (FRPT) stated financial results for its second quarter ended June 30, 2015.
Second Quarter 2015 Financial Highlights Contrast to Preceding Year Period
- Net sales were $28.4 million, up 39.1%
- Adjusted EBITDA raised $3.1 million to $2.8 million
- Freshpet Fridges raised 14.0% to 14,354 from 12,593
First Six Months of Fiscal 2015 Financial Highlights Contrast to Preceding Year Period
- Net sales were $55.4 million, up 39.5%
- Adjusted EBITDA raised $4.4 million to $4.8 million
Freshpet, Inc. manufactures and markets natural fresh foods, refrigerated meals, and treats for dogs and cats in the United States and Canada. The company offers its products under the Freshpet, Dognation, and Dog Joy names. It sells its products through various classes of retail, counting grocery, mass, club, pet specialty, and natural. Freshpet, Inc. was incorporated in 2004 and is headquartered in Secaucus, New Jersey.
MEI Pharma Inc(NASDAQ:MEIP), ended its Thursday’s trading session with 2.69% gain, and closed at $1.91.
MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, declared updated results from a Phase II study of its investigational drug candidate Pracinostat in combination with azacitidine (marketed as Vidaza®) in elderly patients with newly diagnosed acute myeloid leukemia (AML). Data from 50 patients treated at 15 centers are being presented at the European Hematology Association (EHA) Annual Congress in Vienna. A copy of the poster, entitled “Updated Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia,” is now accessible at www.meipharma.com.
MEI Pharma, Inc., an oncology company, focuses on the clinical development of novel therapies for the treatment of cancer. The company’s lead drug candidate is Pracinostat, an orally accessible histone deacetylase inhibitor, which is in Phase II clinical trial for the treatment of hematologic diseases, such as myelodysplastic syndrome and acute myeloid leukemia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
